As Knowledge Ecology International and its allies await the decision of the National Institutes of Health (NIH) on their latest attempt to misuse the Bayh-Dole Act for the government to set prices on any product based on a federally funded invention, they’re growing more uneasy. And that’s understandable. If you’d bet the house on an ivory tower theory that’s been summarily rejected for the past 18 years every time it’s been trotted out, you’d be uneasy too. They know that if the Biden Administration rejects the pending petition to march in on the prostate cancer drug Xtandi because of its cost, this leaky vessel can’t be credibly refloated again.
Business
- Groups on Both Sides Slam USTR Support for Delaying IP Waiver Extension Pending ITC Investigation
- USPTO Ramps Up Efforts to Promote Women Entrepreneurs
- Sign the Prenup: What Brands Can Learn From the Kanye West/Adidas IP Breakup
- Lessons from the Levandowski Case: Reimagining the Exit Interview as Risk Management
- Advocating for Ethics-Driven Regulation for Blockchain Technologies
Recent Posts
- Other Barks & Bites for Friday, February 3: Trump Sues for Copyright Infringement, Google Wins Transfer from TX to CA, and Nike Takes Lululemon to Court for Patent Infringement
- Revolution Rope Inventor Tells Justices She Deserves Her Day in Article III Court
- The USPTO Claims it Wants to Ensure ‘Robust and Reliable’ Patents – But Its Questions Imply Another Assault on Patent Owners
- USPTO Issues Final Rule to Eliminate CLE Certification Program
- This Week in Washington IP: IPWatchdog Event to Review the State of the PTAB; US Inventor Protests in D.C.; and the House Considers Supply Chain Challenges